AANS

American Academy of Orthopaedic Surgeons Introduces the Shoulder & Elbow Registry Powered by PatientIQ

Retrieved on: 
Wednesday, January 31, 2024

ROSEMONT, Ill., Jan. 31, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) has expanded its partnership with PatientIQ to offer Shoulder & Elbow Registry (SER) participants a turnkey solution for data submission. Integration of PatientIQ's cloud-based platform into the SER marks the second AAOS Registry to offer a seamless experience that simplifies the ability to automate the collection and normalization of outcomes data. Together with AAOS, PatientIQ is reducing barriers to tracking evidence-based best practices and advancing the delivery of musculoskeletal care.   

Key Points: 
  • ROSEMONT, Ill., Jan. 31, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) has expanded its partnership with PatientIQ to offer Shoulder & Elbow Registry (SER) participants a turnkey solution for data submission.
  • Together with AAOS, PatientIQ is reducing barriers to tracking evidence-based best practices and advancing the delivery of musculoskeletal care.
  • AAOS Registry Program The AAOS Registry Program's mission is to improve orthopaedic care through the collection, analysis, and reporting of actionable data.
  • Additional registries include the Fracture & Trauma Registry (FTR), the Musculoskeletal Tumor Registry (MsTR), the Shoulder & Elbow Registry (SER), and the American Spine Registry (ASR), a collaborative effort between the American Association of Neurological Surgeons (AANS) and the AAOS.

American Joint Replacement Registry Releases 10th Annual Report

Retrieved on: 
Friday, November 3, 2023

ROSEMONT, Ill., Nov. 3, 2023 /PRNewswire/ -- The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program, published its 2023 Annual Report on hip and knee arthroplasty procedural trends and patient outcomes today. Marking the 10th anniversary edition of the report, the data represents over 3.1 million primary and revision hip and knee arthroplasty procedures performed between 2012 and 2022. This is a 23% growth in procedural cases from the prior report.

Key Points: 
  • ROSEMONT, Ill., Nov. 3, 2023 /PRNewswire/ -- The American Joint Replacement Registry (AJRR), the cornerstone of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program , published its 2023 Annual Report on hip and knee arthroplasty procedural trends and patient outcomes today.
  • Marking the 10th anniversary edition of the report, the data represents over 3.1 million primary and revision hip and knee arthroplasty procedures performed between 2012 and 2022.
  • The American Joint Replacement Registry (AJRR) , the Academy's hip and knee replacement registry, is the cornerstone of the AAOS's Registry Program, and the world's largest national registry of hip and knee joint replacement data by annual procedural count, with more than 3 million procedures contained within its database.
  • Additional registries include the Fracture & Trauma Registry (FTR), the Musculoskeletal Tumor Registry (MsTR), the Shoulder & Elbow Registry (SER), and the American Spine Registry (ASR), a collaborative effort between the American Association of Neurological Surgeons (AANS) and the AAOS.

INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES USING MR-GUIDED FOCUSED ULTRASOUND

Retrieved on: 
Thursday, November 2, 2023

HAIFA, Israel and MIAMI, Nov. 2, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that the editorial panel of the American Medical Association (AMA) approved their application to establish a new Category (Cat) I Current Procedural Terminology (CPT®) code to facilitate reimbursement for MR-guided focused ultrasound (MRgFUS) ablation of neurological targets. The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.

Key Points: 
  • The Cat I CPT® code will be included in the next CPT® codebook and expected to be effective January 1, 2025.
  • "We've long known that focused ultrasound has a significant and valuable role in treating patients with neurological disorders.
  • "This approval can also lead to expanded access to focused ultrasound for US patients," says Dee Kolanek, vice president of market access and reimbursement for Insightec.
  • Focused ultrasound, which was pioneered by Insightec, is FDA approved to treat essential tremor and Parkinsonian tremor.

Dr. Toba N. Niazi Appointed Chief of the Section of Neurosurgery and Co-Director of Nicklaus Children's Brain Institute

Retrieved on: 
Wednesday, October 4, 2023

MIAMI, Oct. 4, 2023 /PRNewswire/ -- Dr. Toba N. Niazi has been appointed Chief of the Section of Neurosurgery for Nicklaus Children's Pediatric Specialists (NCPS) and assumes a leadership position within the Nicklaus Children's Brain Institute as Director of the hospital's Division of Neurosurgery. She will lead the Brain Institute in collaboration with Dr. Paula Schleifer, Director of the Division of Neurology. 

Key Points: 
  • MIAMI, Oct. 4, 2023 /PRNewswire/ -- Dr. Toba N. Niazi has been appointed Chief of the Section of Neurosurgery for Nicklaus Children's Pediatric Specialists (NCPS) and assumes a leadership position within the Nicklaus Children's Brain Institute as Director of the hospital's Division of Neurosurgery.
  • She will lead the Brain Institute in collaboration with Dr. Paula Schleifer, Director of the Division of Neurology.
  • "We honor Dr. Ragheb for his years of leadership and contributions to the Brain Institute and welcome Dr. Niazi to her new role.
  • The national accolades earned by the Nicklaus Children's Brain Institute reaffirms that Nicklaus Children's is the hospital where children matter most.

Glioma in the 7MM: Insights, Epidemiology and Forecast to 2032 - Promising Advances in Treatment and Challenges in Access and Reimbursement - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 24, 2023

The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.

Key Points: 
  • The report offers insights into glioma's epidemiology, current treatments, emerging therapies, market dynamics, and challenges related to treatment access and reimbursement.
  • Epidemiology: Glioma's epidemiology is discussed for the 7MM (United States, EU4 countries, UK, and Japan) from 2019 to 2032.
  • The United States contributed the highest incident cases, with Grade IV glioma being the most prevalent.
  • Market Access and Reimbursement: Reimbursement for rare disease therapies faces challenges due to high costs and lack of policies.

Imperative Care Announces NVQI Registry Data on the Real-World Performance of the Zoom Aspiration Catheters for Ischemic Stroke Treatment

Retrieved on: 
Wednesday, August 2, 2023

The primary goals of the NVQI-QOD registry are to provide a platform for driving improvement in stroke care while meeting the demands set by regulatory agencies and evaluating the safety and clinical performance of medical devices used in treatment of acute ischemic stroke.

Key Points: 
  • The primary goals of the NVQI-QOD registry are to provide a platform for driving improvement in stroke care while meeting the demands set by regulatory agencies and evaluating the safety and clinical performance of medical devices used in treatment of acute ischemic stroke.
  • “We are excited about the opportunity to collaborate with NVQI-QOD to reinforce the safety and effectiveness of our unique angled-tip aspiration catheters for treating patients with ischemic stroke,” said Ariel Sutton, General Manager of Imperative Care’s Stroke business.
  • “Continuing to add to our growing body of evidence with the Zoom Stroke Solution is a priority for Imperative Care.
  • “These real-world data demonstrate that treatment with the Zoom Aspiration Catheters led to high rates of successful reperfusion in patients with ischemic stroke, with no safety concerns.

NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023

Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.

Key Points: 
  • Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.
  • Total operating expenses in the fiscal second quarter 2023 were $3.5 million, compared with $3.0 million in the same period of the prior fiscal year.
  • Research and Development expense in the fiscal second quarter 2023 was $1.7 million compared with $1.2 million in the same period of fiscal 2022.
  • Net loss was $3.5 million for the fiscal second quarter 2023, compared to a net loss of $3.1 million in the prior year period.

ClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023: ClearPoint Maestro® Brain Model and ClearPoint Prism™ Neuro Laser Therapy System

Retrieved on: 
Thursday, April 20, 2023

The ClearPoint Maestro Brain Model will be shown at AANS for the first time since its Limited Market Release.

Key Points: 
  • The ClearPoint Maestro Brain Model will be shown at AANS for the first time since its Limited Market Release.
  • Maestro is designed to enable highly accurate ClearPoint interventions under MRI guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning.
  • The software, which was originally licensed in 2021 from Philips, a global leader in health technology, gained FDA clearance in 2022 .
  • In 2022, CLS received FDA clearance for the ClearPoint Prism Neuro Laser Therapy System .

NICO Corporation's ENRICH Trial Evaluating Minimally Invasive Parafascicular Surgery (MIPS) for Intracerebral Hemorrhage (ICH) to be Presented at the 2023 AANS Annual Scientific Meeting During Plenary Session I

Retrieved on: 
Thursday, April 20, 2023

INDIANAPOLIS, April 20, 2023 /PRNewswire/ -- NICO Corporation, a pioneer and leader in minimally invasive neurosurgery, today announced results from the completed ENRICH (Early MiNimally-invasive Removal of ICH) trial will be presented at the annual American Association of Neurological Surgeons (AANS) meeting in Los Angeles from April 21-24. The ENRICH results were accepted as a late-breaker and will be presented on Saturday, April 22 during an oral plenary session beginning at 8:30 a.m. PT (11:30 a.m. ET) by co-lead ENRICH investigator, Gustavo Pradilla, M.D., associate professor of neurosurgery at Emory University School of Medicine and chief of neurosurgery at Grady Memorial Hospital. 

Key Points: 
  • The ENRICH results were accepted as a late-breaker and will be presented on Saturday, April 22 during an oral plenary session beginning at 8:30 a.m. PT (11:30 a.m.
  • ET) by co-lead ENRICH investigator, Gustavo Pradilla, M.D., associate professor of neurosurgery at Emory University School of Medicine and chief of neurosurgery at Grady Memorial Hospital.
  • BrainPath was the first neurosurgery device to enable minimally disruptive, navigable, trans-sulcal access to the brain while Myriad offers multi-functional capabilities for automated, non-ablative hemorrhage evacuation.
  • As the amount of blood increases , the build-up of pressure can lead to brain damage, unconsciousness or even death.

Aurora Spine to Attend the American Association of Neurological Surgeons Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023

Carlsbad, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be attending the 2023 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.

Key Points: 
  • Carlsbad, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be attending the 2023 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
  • The meeting will be held at April 21-24, 2023, at the Los Angeles Convention Center – Booth #1011.
  • At this year’s AANS event, Aurora Spine will be highlighting its product line, including DEXA-C™, a cervical cage for anterior cervical discectomy with fusion (ACDF) procedures.
  • The SiLO TFX MIS Sacroiliac Joint Fixation System includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation.